 SHANGHAI and SOUTH SAN FRANCISCO, Calif., May 17, 2021 PRNewswire -- Antengene Corporation Limited Antengene, SEHK: 6996.HK, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class andor best-in-class therapeutics in hematology and oncology, and Calithera Biosciences, Inc. Calithera, Nasdaq: CALA, a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced an exclusive, worldwide license agreement for the development and commercialization of CB-708 ATG-037, Calitheras small molecule inhibitor of CD73. 